ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.045

-3.1%

1:53 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jargonweary who wrote (962)	4/15/2025 5:43:25 PM
From: Olecranon	of 1229

This is probably the only “blockbuster news”. It was published this morning. ImmunityBio Completes FDA License Application Submissions MT Newswires 10:40 AM EDT, 04/15/2025 (MT Newswires) -- ImmunityBio (IBRX.NaE) said Tuesday it completed submissions to the US Food and Drug Administration, including the supplemental biologics license application for ANKTIVA plus Bacillus Calmette-Guerin to treat BCG-unresponsive non-muscle invasive bladder cancer in papillary disease. The company also submitted an expanded access protocol to the FDA to make ANKTIVA available for the treatment of lymphopenia, according to a statement. ImmunityBio (IBRX.NaE) also reported preliminary net product revenue of about $16.5 million for Q1, up from $7.2 million in Q4. Price: 2.91, Change: +0.02, Percent Change: +0.69 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next